Dermatology Times

DECEMBER 10, 2024

Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.

Dermatitis 36

Dermatitis Clinic Therapy Management 36

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

The Dermatology Digest

APRIL 1, 2025

We have seen immense therapeutic innovation in the treatment of AD, PN, and chronic CSU, over the past decade, the reviews first author Raj Chovatiya, MD, PhD, MSCI,Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago,tells The Dermatology Digest.

Dermatitis 36

Dermatitis Dermatology Therapy Tools 36

Dermatology Times

DECEMBER 4, 2024

Gina Mangin, MPAS, PA-C, discusses how developing an effective atopic dermatitis treatment plan requires a personalized, multifaceted approach that combines proper skin care, trigger avoidance, topical medications, and potentially systemic therapies based on the severity of symptoms and individual patient needs.

Dermatitis 36

Dermatitis Treatments Therapy Medical 36

Aesthetics Advisor

FEBRUARY 23, 2025

Alexs eczema, also known as atopic dermatitis, began in infancy with small, itchy patches on his wrists and handsa condition Kate, a seasoned nurse, was familiar with. Her decision to stop his medication was supported by medical professionals but is still controversial in some circles. Desai in a statement to The Epoch Times.

Eczema 36

Eczema Dermatitis Medical Clinic 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024. “The

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

FEBRUARY 26, 2024

2 In this review, we highlight the “epithelial barrier hypothesis” proposed by Akdis, discuss the important roles of the skin, gut, and respiratory barriers, and discuss novel therapies. Impairment in tight junction expression has been shown to contribute to the barrier dysfunction observed in patients with atopic dermatitis.

Dermatitis 74

Dermatitis Irritation Therapy Moisturization 74

US Dermatologt Partners

AUGUST 23, 2023

Atopic Dermatitis, more commonly known as eczema, is a common skin condition impacting one in 10 Americans. Dermatology Partners affiliate office Medical Dermatology Specialists in Phoenix, Arizona , “Like other chronic skin conditions, eczema is best managed with the help of a dermatologist. Millions of people in the U.S.

Eczema 36

Eczema Dermatitis Management Skin Health 36

First Derm

JUNE 23, 2024

1] Three main categories of eczema are atopic eczema, contact dermatitis and stasis dermatitis. To prevent that your dermatologist will advice you to slowly taper off the topical steroid, shift from high to mild potency ones, or every other day therapy. The American Contact Dermatitis Society recognizes it as an allergen.

Eczema 59

Eczema Ingredients Dermatitis Irritation 59

US Dermatologt Partners

NOVEMBER 25, 2023

Atopic dermatitis (AD) is a multifaceted condition that can significantly impact a patient’s quality of life. I think that dermatitis started showing up once my psoriasis started showing up,” Dean said. “It As a physician, I have to do a better job intervening here [and] switch our systemic therapies.”

Dermatitis 36

Dermatitis Therapy Networking Treatments 36

First Derm

MARCH 22, 2024

Eczema herpeticum Medically reviewed by The Dermatologists and written by Dr. Alexander Börve In A Nutshell What It Is : Skin infection marked by fever and clusters of itchy blisters, often complicating atopic dermatitis. Those with atopic dermatitis have lower resistance to the herpes infection. What is Eczema Herpeticum?

Eczema 52

Eczema Dermatitis Clinic Medical 52

Dermatology Times

JANUARY 13, 2025

A panelist discusses how combining different therapeutic approaches, such as topical agents with systemic medications, can provide optimal control for patients with severe atopic dermatitis while managing both acute flares and long-term disease maintenance.

Therapy 36

Therapy Dermatitis Management Medical 36

The Dermatology Digest

MARCH 11, 2024

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best.

Dermatitis 69

Dermatitis Eczema Dermatology Pharmaceutical 69

The Dermatology Digest

JANUARY 29, 2024

From new topical therapies and novel biologics including nemolizumab and lebrikizumab to OX40 and OX40 ligand monoclonal antibodies, the atopic dermatitis pipeline is full, says Andrew Blauvelt, MD, MBA, an Investigator at Oregon Medical Research Center in Portland. appeared first on The Dermatology Digest.

Dermatitis 28

Dermatitis Therapy Medical Dermatology 28

American Esthetician Organization

AUGUST 21, 2023

It can occur due to a variety of reasons, such as exposure to harsh weather conditions, excessive sun exposure, hormonal changes, and even certain medical conditions. Eczema, also known as atopic dermatitis, is a chronic skin condition characterized by dry, itchy, and inflamed skin.

Rosacea 88

Rosacea Facials Skincare Routine Irritation 88

The Dermatology Digest

FEBRUARY 1, 2024

Atopy patch tests (APTs) may be the best way to detect food‐triggered atopic dermatitis (AD), according to a new literature review in Clinical Reviews in Allergy & Immunology. APTs detect sensitization to food proteins responsible for systemic contact dermatitis (SCD), which can then be confirmed by oral food challenge.

Dermatitis 36

Dermatitis Eczema Medical Therapy 36

First Derm

FEBRUARY 6, 2024

Over time, the prolonged use of these medications can lead to TSW, resulting in a range of distressing symptoms such as redness, itching, and skin sensitivity. Topical Steroid Withdrawal (TSW) is a condition that occurs when a person stops using topical steroids, which are medications applied to the skin to reduce inflammation and itching.

Treatments 59

Treatments Dermatitis Management Skin Issues 59

First Derm

MARCH 8, 2023

However, in some cases, itchy feet can be a sign of an underlying health condition that requires medical attention. Itchy feet can be a sign of an underlying health condition that requires medical attention. Skin-related causes include athlete’s foot, eczema, psoriasis, contact dermatitis, scabies, and fungal infections.

Eczema 52

Eczema Dermatitis Medical Dry Skin 52

First Derm

JULY 2, 2024

Online Dermatologist Sweating and Eczema: How to Manage Flare-Ups Eczema and Sweat | Symptoms of eczema | Physiology | How Sweating Affects Eczema | Triggers for Eczema | Related conditions | Managing Sweat to Prevent Eczema Flare-Ups | Treatment Key Takeaways Eczema, particularly atopic dermatitis, flares up with triggers like sweat.

Eczema 45

Eczema Management Dermatitis Irritation 45

First Derm

APRIL 5, 2024

Ensuring adherence to therapies in dermatology is paramount for enhancing treatment efficacy and promoting patient well-being. For instance, polypharmacy in acne treatment can lead to difficulties in remembering to take medications as scheduled, affecting both primary and secondary adherence.

Dermatology 45

Dermatology Treatments Education Medical 45

The Dermatology Digest

JUNE 27, 2024

Eczema is known to take a toll on emotional wellbeing and quality of life, yet 42% of patients with atopic dermatitis (AD) and caregivers of children/teens with eczema have never spoken about mental health with primary eczema care providers, according to new survey results from The National Eczema Association (NEA) in Skin Health and Disease.

Eczema 36

Eczema Dermatitis Therapy Office 36

The Dermatology Digest

DECEMBER 14, 2024

Food and Drug Administration approved two new therapies for atopic dermatitis (AD): Nemolizumab (Nemluvio, Galderma) and tapinarof cream, 1% (Vtama, Organon). Ted Rosen, MD, is a Professor of Dermatology at Baylor College of Medicine in Houston, TX, and the Medical Editor of the Dermatology Digest.

Dermatitis 36

Dermatitis Injections Dermatology Therapy 36

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. The most frequently reported TEAEs included nasopharyngitis, acne, upper respiratory tract infection, and atopic dermatitis.

Treatments 36

Treatments Dermatitis Pharmaceutical Eczema 36

The Dermatology Digest

JULY 10, 2024

for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

DECEMBER 18, 2023

New practice parameters from the Joint Task Force for Practice Parameter) recommend the use of topical corticosteroids or topical calcineurin inhibitors in patients with uncontrolled atopic dermatitis (AD) despite moisturizer use. Urge consideration for once-daily dosing of topical medications. Suggest against elimination diets for AD.

Dermatitis 36

Dermatitis Partnerships Therapy Diet 36

The Dermatology Digest

APRIL 10, 2024

Sitryx Therapeutics plans to advance SYX-5219, an oral, targeted, disease-modifying anti-inflammatory therapy that targets pyruvate kinase M2 (PKM2), to the clinic. Sitryx is making great progress with its lead candidate, SYX-5219, an oral and novel targeted therapy with the potential to deliver significant benefit to patients.”

Clinic 36

Clinic Office Partnerships Dermatitis 36

The Dermatology Digest

MARCH 11, 2024

Tralokinumab (Adbry, Leo Pharma) provides stable long-term control of atopic dermatitis (AD), new research shows. Atopic dermatitis (AD) is a chronic disease requiring control over time. tells TDD.

Dermatitis 36

Dermatitis Eczema Dermatology Consultation 36

The Dermatology Digest

JANUARY 7, 2024

Led by Louisville, KY dermatologist Joe Fowler, MD, and George Martin, MD, a dermatologist in Kihei, HI, and Maui Derm Program Chairman, the four-day meeting will feature treatment updates on psoriasis, atopic dermatitis, acne/rosacea, pigmentation disorders, blistering diseases, pediatric dermatology and more. In this session, Drs.

Dermatitis 36

Dermatitis Dermatology Rosacea Hospital 36

The Dermatology Digest

MARCH 9, 2024

Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, discusses the role that abrocitinib (Cibinqo, Pfizer) and upadacitinib (Rinvoq, AbbVie) play in treating patients with atopic dermatitis (AD). Watch Now Biosimilars in Dermatology: Where Do They Fit in?

Dermatitis 36

Dermatitis Eczema Dermatology Clinic 36

The Dermatology Digest

MARCH 9, 2024

Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, discusses the role that abrocitinib (Cibinqo, Pfizer) and upadacitinib (Rinvoq, AbbVie) play in treating patients with atopic dermatitis (AD). Watch Now Biosimilars in Dermatology: Where Do They Fit in?

Dermatitis 36

Dermatitis Eczema Dermatology Clinic 36

First Derm

MAY 11, 2023

Contact dermatitis : This occurs when the skin comes into contact with an irritant, such as a certain type of fabric, detergent, or perfume, and causes a rash. Allergic reactions: Some people may develop a rash on the breast due to an allergic reaction to a food, medication, or cosmetic product.

Irritation 40

Irritation Eczema Dermatitis Medical 40

The Dermatology Digest

MARCH 11, 2024

Atopic dermatitis (AD) is extremely common, but it can resemble psoriasis, urticaria, non-blistering immunobolus disease, cutaneous lymphoma, and many other skin conditions. Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Watch Now The Lowdown on Molluscum Nanette B.

Dermatitis 36

Dermatitis Eczema Dermatology Pharmaceutical 36

The Dermatology Digest

DECEMBER 18, 2023

Air pollution may contribute to the development or worsening of skin conditions such as atopic dermatitis and eczema, according to researchers out of Massachusetts General Hospital (MGH). Carbon monoxide concentrations that were an average of 0.22 ppm in the months of May–September in 2019–2022 rose to 0.6 ppm in July of 2023.

Eczema 36

Eczema Dermatitis Hospital Dermatology 36

The Dermatology Digest

MARCH 10, 2024

Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, shares pearls on keeping pediatric patients comfortable during common dermatologic procedures. From distraction techniques to pharmacologic measures, Peter A.

Dermatology 36

Dermatology Dermatitis Eczema Clinic 36

The Dermatology Digest

MARCH 13, 2024

Genodermatoses can masquerade as atopic dermatitis (AD). Raj Chovatiya, MD, PhD Atopic dermatitis (AD) is extremely common, but it can resemble psoriasis, urticaria, non-blistering immunobolus disease, cutaneous lymphoma, and many other skin conditions. Watch Now Rational Combinations in Acne James Q. Lio, MD Peter A.

Dermatitis 36

Dermatitis Dermatology Clinic Eczema 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Topical or systemic AD medications were not permitted during the study.

Safety 36

Safety Therapy Dermatitis Eczema 36

The Dermatology Digest

MARCH 11, 2024

Joshua Zeichner, MD, Associate Professor of Dermatology at the Mount Sinai Hospital in New York City, reviews the latest information on prescribing and monitoring isotretinoin for patients with severe nodulocystic acne and provides an update on the potential risks associated with this medication. Watch Now The Lowdown on Molluscum Nanette B.

Dermatitis 36

Dermatitis Eczema Dermatology Pharmaceutical 36